Retrospective Evaluation of Different Antiviral Treatments for Chronic Hepatitis C Infection
Introduction: The standard treatment for patients with chronic hepatitis C is a 6-12 months combination therapy with interferon-alpha (IFN-α) and ribavirin. The aim of this study was to evaluate different antiviral treatments for chronic hepatitis C. Patients and Methods: In this study, we compared...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bilimsel Tip Yayinevi
2008-09-01
|
| Series: | Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi |
| Subjects: | |
| Online Access: | http://www.floradergisi.org/getFileContent.aspx?op=REDPDF&file_name=2008-13-3-122-129.pdf |
| _version_ | 1797923420380332032 |
|---|---|
| author | Orhan YILDIZ Bilgehan AYGEN Emine ALP Selma GÖKAHMETOĞLU Işın SOYUER |
| author_facet | Orhan YILDIZ Bilgehan AYGEN Emine ALP Selma GÖKAHMETOĞLU Işın SOYUER |
| author_sort | Orhan YILDIZ |
| collection | DOAJ |
| description | Introduction: The standard treatment for patients with chronic hepatitis C is a 6-12 months combination therapy with interferon-alpha (IFN-α) and ribavirin. The aim of this study was to evaluate different antiviral treatments for chronic hepatitis C. Patients and Methods: In this study, we compared the outcome of chronically infected hepatitis C virus patients (n= 130) who received different doses of IFN-α monotherapies or IFN-α plus ribavirin combination therapies. Patients received one of the following treatment regimens: group M.I (n= 5): 3 MU IFN α2b thrice weekly; group M.II (n= 17): 5-6 MU IFN-α2a/2b thrice weekly; group M.III (n= 19): Daily interferon-α2a/2b (5-6 MU per day for 12 weeks then 3-5 MU thrice weekly); group K.I (n= 60): 3 MU IFN-α2b thrice weekly plus 1000-1200 mg/day ribavirin; group K.II (n= 7): 5-6 MU IFN-α2a/2b thrice weekly plus 1000-1200 mg/d ribavirin; group K.III (n= 22): Daily interferon-α2a/2b (5-6 MU per day for 12 weeks then 3-5 MU thrice weekly) plus 1000-1200 mg/day ribavirin. Patients were treated for 12 months and observed for six months of posttreatment period. Results: The virological responses at the end of treatment were 40% in the group M.I, 88.2% in the group M.II, 75% in the group M.III, 88.1% in the group K.I, 85.7% in the group K.II and 64.7% in the group K.III (p= 0.044). The subgroup analysis showed that the virological response was significantly higher in group K.I than in group M.I (p= 0.024). The sustained responses were 40% in the group M.I, 64.7% in the group M.II, 66.7% in the group M.III, 71.2% in the group K.I, 71.4% in the group K.II and 50% in the group K.III (p> 0.05). Conclusion: In conclusion; sustained virological clearence was detected slightly more in the combination therapy with higher IFN dosage plus ribavirin. |
| first_indexed | 2024-04-10T14:46:06Z |
| format | Article |
| id | doaj.art-abaf0f5554ae4f15a61c8557cbcdd54c |
| institution | Directory Open Access Journal |
| issn | 1300-932X 1300-932X |
| language | English |
| last_indexed | 2024-04-10T14:46:06Z |
| publishDate | 2008-09-01 |
| publisher | Bilimsel Tip Yayinevi |
| record_format | Article |
| series | Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi |
| spelling | doaj.art-abaf0f5554ae4f15a61c8557cbcdd54c2023-02-15T16:07:52ZengBilimsel Tip YayineviFlora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi1300-932X1300-932X2008-09-01133122129Retrospective Evaluation of Different Antiviral Treatments for Chronic Hepatitis C InfectionOrhan YILDIZ0Bilgehan AYGEN1Emine ALP2Selma GÖKAHMETOĞLU3Işın SOYUER4Erciyes Üniversitesi Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim DalıErciyes Üniversitesi Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim DalıErciyes Üniversitesi Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim DalıErciyes Üniversitesi Tıp Fakültesi, Mikrobiyoloji ve Klinik Mikrobiyoloji Anabilim DalıErciyes Üniversitesi Tıp Fakültesi, Patoloji Anabilim Dalı, KAYSERİIntroduction: The standard treatment for patients with chronic hepatitis C is a 6-12 months combination therapy with interferon-alpha (IFN-α) and ribavirin. The aim of this study was to evaluate different antiviral treatments for chronic hepatitis C. Patients and Methods: In this study, we compared the outcome of chronically infected hepatitis C virus patients (n= 130) who received different doses of IFN-α monotherapies or IFN-α plus ribavirin combination therapies. Patients received one of the following treatment regimens: group M.I (n= 5): 3 MU IFN α2b thrice weekly; group M.II (n= 17): 5-6 MU IFN-α2a/2b thrice weekly; group M.III (n= 19): Daily interferon-α2a/2b (5-6 MU per day for 12 weeks then 3-5 MU thrice weekly); group K.I (n= 60): 3 MU IFN-α2b thrice weekly plus 1000-1200 mg/day ribavirin; group K.II (n= 7): 5-6 MU IFN-α2a/2b thrice weekly plus 1000-1200 mg/d ribavirin; group K.III (n= 22): Daily interferon-α2a/2b (5-6 MU per day for 12 weeks then 3-5 MU thrice weekly) plus 1000-1200 mg/day ribavirin. Patients were treated for 12 months and observed for six months of posttreatment period. Results: The virological responses at the end of treatment were 40% in the group M.I, 88.2% in the group M.II, 75% in the group M.III, 88.1% in the group K.I, 85.7% in the group K.II and 64.7% in the group K.III (p= 0.044). The subgroup analysis showed that the virological response was significantly higher in group K.I than in group M.I (p= 0.024). The sustained responses were 40% in the group M.I, 64.7% in the group M.II, 66.7% in the group M.III, 71.2% in the group K.I, 71.4% in the group K.II and 50% in the group K.III (p> 0.05). Conclusion: In conclusion; sustained virological clearence was detected slightly more in the combination therapy with higher IFN dosage plus ribavirin.http://www.floradergisi.org/getFileContent.aspx?op=REDPDF&file_name=2008-13-3-122-129.pdfChronic hepatitis CInterferonInductionCombinationRibavirin |
| spellingShingle | Orhan YILDIZ Bilgehan AYGEN Emine ALP Selma GÖKAHMETOĞLU Işın SOYUER Retrospective Evaluation of Different Antiviral Treatments for Chronic Hepatitis C Infection Flora Infeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi Chronic hepatitis C Interferon Induction Combination Ribavirin |
| title | Retrospective Evaluation of Different Antiviral Treatments for Chronic Hepatitis C Infection |
| title_full | Retrospective Evaluation of Different Antiviral Treatments for Chronic Hepatitis C Infection |
| title_fullStr | Retrospective Evaluation of Different Antiviral Treatments for Chronic Hepatitis C Infection |
| title_full_unstemmed | Retrospective Evaluation of Different Antiviral Treatments for Chronic Hepatitis C Infection |
| title_short | Retrospective Evaluation of Different Antiviral Treatments for Chronic Hepatitis C Infection |
| title_sort | retrospective evaluation of different antiviral treatments for chronic hepatitis c infection |
| topic | Chronic hepatitis C Interferon Induction Combination Ribavirin |
| url | http://www.floradergisi.org/getFileContent.aspx?op=REDPDF&file_name=2008-13-3-122-129.pdf |
| work_keys_str_mv | AT orhanyildiz retrospectiveevaluationofdifferentantiviraltreatmentsforchronichepatitiscinfection AT bilgehanaygen retrospectiveevaluationofdifferentantiviraltreatmentsforchronichepatitiscinfection AT eminealp retrospectiveevaluationofdifferentantiviraltreatmentsforchronichepatitiscinfection AT selmagokahmetoglu retrospectiveevaluationofdifferentantiviraltreatmentsforchronichepatitiscinfection AT isınsoyuer retrospectiveevaluationofdifferentantiviraltreatmentsforchronichepatitiscinfection |